HLB Therapeutics Co Ltd
HLB Therapeutics Co Ltd is a South Korean pharmaceutical company that develops and commercializes therapeutic products, primarily in the biotechnology and pharmaceuticals sectors.
Business. HLB Therapeutics Co Ltd (115450.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. As specific operating segment and geographic revenue data are not disclosed, the company is described at the industry level within the Healthcare sector. Its business model focuses on product sales within the Pharmaceuticals & Medical Research industry.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
HLB Therapeutics Co Ltd (115450.KQ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. As specific operating segment and geographic revenue data are not disclosed, the company is described at the industry level within the Healthcare sector. Its business model focuses on product sales within the Pharmaceuticals & Medical Research industry.
HLB Therapeutics has a current liquidity position that is medium, with a cash and equivalents balance of KRW 20.31 billion and a negative free cash flow of KRW -15.11 billion. The company's debt-to-equity ratio is 0.27, indicating a relatively low level of leverage compared to its equity base. The current ratio of 2.84 suggests the company has sufficient short-term assets to cover its short-term liabilities.
The company's profitability is weak, with a return on equity of -6.14% and a return on assets of -4.04%. These figures indicate that HLB Therapeutics is not generating returns that exceed its cost of capital, and is currently operating at a loss. The operating income is negative at KRW -6.97 billion, and the net income is also negative at KRW -9.23 billion.
HLB Therapeutics does not disclose specific segment or geographic revenue breakdowns in the provided data, so it is not possible to assess revenue concentration or geographic exposure at this time. The company's business is primarily focused on pharmaceuticals and medical research, with no clear indication of diversification across multiple therapeutic areas or markets.
The company's growth trajectory is uncertain, as it is currently reporting negative operating and net income. There are no specific numeric deltas provided for the current or next fiscal year to assess growth direction. The company's capital expenditures are negative at KRW -10.07 billion, suggesting a reduction in investment in long-term assets.
HLB Therapeutics faces a medium liquidity risk, as its free cash flow is negative and its operating cash flow is also negative at KRW -8.18 billion. The company's dilution risk is low, with no significant dilution sources identified in the provided data. The company has not issued additional shares recently, and there is no indication of a pending equity offering or other dilutive event.
There are no recent events or filings provided in the data to assess the company's strategic direction or operational changes. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.
- HLB Therapeutics is currently operating at a loss, with negative operating and net income.
- The company has a relatively low debt-to-equity ratio, but its liquidity position is medium due to negative free cash flow.
- There is no clear indication of geographic or segment revenue concentration in the provided data.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
- HLB Therapeutics faces a medium liquidity risk and a low dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- HLB Therapeutics Co Ltd Market data — financials · 2026-05-26